Peripheral Arteriovenous Malformations: Imaging and Endovascular Management Strategies

Virender Malik 1, Harshith Kramadhari 2, Jawahar Rathod 3, Yadav W. Munde 4, Uday Bhanu Kovilapu 5

1 Army Institute of Cardiothoracic sciences (AICTS), affiliated to Armed Forces Medical College, Pune, India
2 KS Hegde Medical Academy, Derlakatte, Mangalore, India
3 Government Medical College and Hospital, Nagpur, India
4 Ruby Hall Clinic, Pune, India
5 Armed Forces Medical College, India

Address for correspondence Yadav W. Munde, MD (Rad), Chief Interventional Radiologist, Department of Interventional Radiology, 6th Floor, Cancer Centre, Ruby Hall Clinic, Sasoon Road, Pune 411001, India (e-mail: yadavmunde@gmail.com).

Abstract

The peripheral high-flow vascular malformation (HFVM) comprises arteriovenous malformation (AVM) and fistula (AVF), shows varied clinical presentation (ranging from subtle skin lesion to life-threatening congestive heart failure), and frequently poses diagnostic and therapeutic challenges. Importance of assigning a specific diagnosis to the vascular malformation cannot be overstated, as the treatment strategy is based on the type of vascular anomaly. Although the International Society for the Study of Vascular Anomalies (ISSVA) classification system is the most commonly accepted system for classifying congenital vascular anomalies in clinical practice, the Cho–Do et al classification is of utmost help in guiding optimal mode of treatment in peripheral AVM. Although transarterial approach remains the most commonly employed route for peripheral AVM embolization, the role of transvenous and direct percutaneous approach is ever increasing and the final decision on the approach depends on angioarchitecture of the AVM. In this article, we review various commonly employed classification systems for congenital vascular anomalies, and describe clinical features, imaging and treatment strategies for peripheral arteriovenous malformation (PAVM).

Introduction

The peripheral high-flow vascular malformation (HFVM) comprises arteriovenous malformation (AVM) and fistula (AVF), shows varied clinical presentation (ranging from subtle skin lesion to life-threatening congestive heart failure), and frequently poses diagnostic and therapeutic challenges. The importance of assigning a specific diagnosis to the vascular malformation cannot be overstated, as the treatment strategy is based on the type of vascular anomaly. In this article, we review various commonly employed classification systems for congenital vascular anomalies, and describe clinical features, imaging and treatment strategies for peripheral arteriovenous malformation (PAVM).

Classification Systems for Congenital Vascular Anomalies

Various classification systems have been in use with the aim of providing standard universal terminology, making accurate diagnosis and thereby optimizing treatment strategy. The widely accepted classification, proposed by Mulliken and Glowacki in 1982, is a biological classification, based on the histologic features, natural history and physical findings. This classification assigns particular nomenclature to...
the vascular anomalies, based on the preponderant vascular channel (capillary, venous lymphatic, arterial, or combined) and differentiates hemangioma from vascular malformation, based on the degree of cellular turnover and presence or absence of dysplastic vascular channels. Subsequently, in 1993 Jackson et al proposed a classification, based on the parameter of flow dynamics, classifying vascular anomalies as low-flow or high-flow malformations. The International Society for the Study of Vascular Anomalies (ISSVA), in 1996, adopted and expanded these systems, considering vascular tumors and vascular malformations as two different broad categories; further, it subcategorized the latter as low- and high-flow malformations, based on the flow dynamics.

The presence or absence of arterial component classifies lesions as high- and low-flow malformations, respectively, with endovascular being the preferred route of treatment in the former, while direct sclerotherapy for the latter group.

The 2014 ISSVA Classification of Vascular anomalies incorporated recent advances in the genetic and pathologic characteristics of these diseases and grouped lesions as simple, combined and truncular vascular malformations along with manifestation of these malformations as part of a syndrome (Table 1). The simple and combined vascular malformations are characterized by involvement of only one type of vessel or a combination of various vessel types, respectively.

Cho–Do et al and Yakes recently introduced classification systems for AVM, based on morphology of AVM and is helpful in guiding optimal mode of treatment.

### Clinical Presentation

HFVM comprises AVM and AVF, with the most common presentation noted in the late childhood as a red, pulsatile, warm mass with a thrill and grows proportionally with the child without regression. The AVMs characteristically comprise feeding arteries, nidus, and draining veins. The AVFs are characterized by a single vascular channel between an artery and a vein. The AVMs, although present at birth, usually manifest later, as the lesion increases proportionate to child growth, with exacerbations noted consequent to hormonal changes (puberty or pregnancy), infection, thrombosis, or trauma. The presentation may be varied, ranging from asymptomatic or minimal dermatologic features (cutaneous blush or warmth) to high-output cardiac failure. The Schobinger staging system is a four-stage AVM classification, based on clinical manifestations of an AVM, ranging from minor dermatologic findings in stage I to high-output cardiac failure in stage IV.

The proliferating phase of infantile hemangiomas is also a high-flow lesion but categorized as a vascular tumor (not malformation) which shows regression over time, unlike vascular malformations. Whereas presence of limb length or size discrepancy suggests Parkes–Weber syndrome, the macrocephalia and hamartoma are indicators of Cowden syndromes. The presence of multiple intramuscular AVMs, ectopic fat overgrowth, and intracranial developmental anomalies are some of the pointers to a syndromic association in peripheral AVM.

### Imaging Modalities

Although the plain radiographs play a limited role in classifying the vascular malformations, the presence of phleboliths strongly suggest diagnosis of venous malformations or hemangioma. Gray-scale ultrasound (US) and Doppler are usually the initial imaging modalities undertaken, providing a differentiation not only between hemangiomas and vascular malformations, but also a more important treatment guiding distinction between low and high flow vascular malformations. Presence of arterial spectral waveform, turbulent multidirectional flow of blood, spectral broadening and shunts indicate a HFVM. Posttreatment Doppler study by assessing the arterial flow can determine the success of the
The limited field of view, suboptimal evaluation of deeper placed lesions, and operator dependency are few of the limitations with this technique.\(^6\)

MRI is the most valuable imaging modality aiding in accurate classification of vascular anomalies.\(^20\) By defining the extent of lesion, its anatomic relationship to important adjacent structures, providing differentiation between low and high-flow malformations, and allowing detailed assessment of angioarchitecture, MR imaging helps not only in accurate diagnosis but also plays an important role in treatment planning.\(^21\)

The sequences with specific information provided by each is summarized in Table 2.

Table 2  MR sequences for detailed evaluation of vascular malformations

<table>
<thead>
<tr>
<th>MRI Sequence</th>
<th>Specific information obtained</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>SE or fast SE T1-W</td>
<td>Basic anatomic evaluation</td>
<td></td>
</tr>
<tr>
<td>FS fast SE T2-W or STIR</td>
<td>Assess lesion extension</td>
<td>Exquisitely define the extent of vascular malformations</td>
</tr>
<tr>
<td>GRE T2 *-W</td>
<td>Calcification or hemosiderin</td>
<td>Calcification or hemosiderin appear as intense focal hypointensities Signal in blood vessel on GRE sequence: - Absent (low-flow malformation) - High (high-flow malformation)</td>
</tr>
<tr>
<td>3D T1-W fast GRE CE MRA</td>
<td>Angioarchitecture assessment</td>
<td>Evaluate perfusion of the lesion Imaging performed in arterial and multiple venous phases (early, intermediate, and late) with 30 sec delay between each.</td>
</tr>
<tr>
<td>Dynamic time-resolved MR angiography</td>
<td>Excellent depiction of angioarchitecture and assessment of hemodynamic properties of vascular malformations</td>
<td>Involves creative acquisition of k-space Multiple data sets acquisition (one 3D dataset every 2 seconds) high temporal and spatial resolution permits separation of arterial inflow from venous drainage, detection of early venous shunting, and contrast material arrival time information</td>
</tr>
<tr>
<td>Unenhanced and delayed contrast enhanced FS 3D T1-W GRE (delay of 5-10 minutes)</td>
<td>Provides high spatial resolution images of both the vascular system and the surrounding soft tissues</td>
<td>Uses reduced flip angle Provides nearly isotropic resolution Depicts the drainage of malformation in the venous system, help to evaluate very-low-flow malformations.</td>
</tr>
</tbody>
</table>

Abbreviations: CE MRA, contrast-enhanced magnetic resonance angiography; FS, fat-suppressed; GRE, gradient echo; STIR, short Tau inversion recovery; T1W, T1-weighted; T2-W, T2-weighted.

The presence of a well-defined lobulated masses showing high signal intensity (SI) on T2-W, intermediate SI on T1-W, flow voids on T2-W, early intense and uniform enhancement with absence of arteriovenous shunting and perilesional edema are characteristic features of proliferative phase of hemangiomas.\(^19,22\) The presence of enlarged feeding arteries and draining veins, visualized as large flow voids (SE images) or high SI areas (gradient echo [GRE] images) with no definite mass lesion, are useful findings to classify the lesion as a HFVM. Dynamic time-resolved MR angiography, by providing information about hemodynamic properties of vascular malformations, excellent depiction of angioarchitecture, separation of arterial inflow from venous drainage, and detection of early venous shunting allow accurate classification of HFVM as either proliferative phase of hemangioma, AVM, or AVF. The AVM with intraosseous extension appears as decreased SI of marrow on T1-W images.\(^12\) Differentiating long-standing secondary AVFs from AVMs can be challenging, as the more proximal feeding arteries and distal draining veins enlarge over time in the former.

The AVM is visualized as a high-density area on plain CT with the nidus depiction and evidence of shunting appreciated on CT angiography (CTA). Despite higher temporal resolution and less procedural time of CTA compared to conventional magnetic resonance angiography (MRA), MRI is the preferred modality due to better soft-tissue characterization and absence of ionizing radiation risk.\(^21\)

The catheter angiography remains the gold standard to evaluate the flow dynamics and angioarchitecture of the nidus, effectively aiding in optimization of treatment approach.\(^21\) Although angiography is generally undertaken for well worked-up patients with documented definitive indication for radiological intervention, its usage as primary diagnostic confirmatory imaging tool in atypical cases is not uncommon.

Treatment of High-flow Vascular Malformations (HFVM)

The importance of differentiation between low-flow vascular malformation (LFVM) and HFVM cannot be overstated as the usual treatment of choice for former is percutaneous sclerotherapy, whereas the endovascular approach is needed for the latter.\(^3,10,11,21,24\) Identifying the lesion as LFVM is more important than determining the specific type of vascular channel it contains, as the treatment for both venous and lymphatic malformation is nearly identical (direct percutaneous sclerotherapy).\(^1,11,13,25,26\)

The classical Schobinger stage I lesion is clinically quiescent and is usually managed with observation and close follow-up. Considering the symptomatology and weighing risk-benefit ratio, treatment could be undertaken and individualized for stage II patients. Early treatment is considered necessary for HFVM with presence of hemorrhage, high-output cardiac failure, chronic venous hypertension, disabling pain, functional disability, or cosmetic deformities.\(^1,10,11\) Liu et al observed progressive increase in Schobinger stage of AVM, with most worsening clinically before
adulthood, emphasizing importance of an early definite treatment.²⁷ The high morbidity and recurrence rate associated with surgical procedures, ever improving interventional hardware (permitting superselective techniques), and liquid embolic agents (►Table 3) have led to acceptance of endovascular techniques as the preferred mode of management of the peripheral AVM and AVF.²,²⁸

Whatever may be the approach chosen, complete obliteration of the nidus, hence arteriovenous shunting, remains the primary goal of endovascular treatment of AVMs. Although percutaneous approach to nidus is commonly undertaken in AVM, its usage is predominantly supplementary, with endovascular route being the primary mode of embolization.¹⁹

► Fig. 2 and ►Table 4 illustrates the key characteristics of the Cho–Do et al classification, emphasizing its influence on selecting an appropriate mode of endovascular management (►Fig. 3 and ►Table 4).

Although transelective approach is the most commonly employed route for AVM embolization, the final decision on the approach depends on angioarchitecture of the AVM. Type I AVMs have three or fewer feeding arteries shunting into a single draining vein. AVM with such morphology can be treated using either a transelective or transvenous approach. Type II AVMs demonstrate arteriovenous nidus structure, wherein multiple arterioles shunt blood into a single draining vein. As the vein in this type is usually much larger than the feeding arteries, transvenous approach becomes the preferred route in type 2 AVM.³¹ Type IIIa and IIIb both show arteriovenous nidus structure with absence and presence of dilatation of vascular channels, respectively. Although Type IIIa can be treated only with a transelective approach, type IIIb can be embolized using either transelective, transvenous, or direct percutaneous approaches.⁷ ► Fig. 3 illustrates the endovascular management employed, based on the AVM nidus type (Cho–Do classification system).

Arterial treatments of AVMs may be undertaken either with the aim of achieving complete obliteration through transelective route or as a supplementary treatment.³⁴–³⁶ The standalone arterial approach (►Fig. 4) and combined (►Figs. 5 and 6) arterial and percutaneous approach are commonly undertaken strategies in PAVM management.

The arterial approach as an adjunctive in PAVM treatment involves initial deployment of balloons, coils, plugs, or liquid embolizing agents in the feeding arteries, thus inducing local hypotension in the nidus (►Fig. 7). This increases the chances of complete obliteration of the AVM following direct cutaneous or transvenous retrograde AVM embolization (TRA) approaches subsequently.³⁴–³⁶ The reduction of nidal flow achieved by initial adjunctive arterial approach helps achieve

---

### Table 3

<table>
<thead>
<tr>
<th>Embolic agent</th>
<th>Onyx</th>
<th>n-BCA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical composition</td>
<td>EVOH²⁹</td>
<td>n-BCA</td>
</tr>
<tr>
<td>Priming agent</td>
<td>DMSO (catheter primed with DMSO)</td>
<td>Dextrose (catheter primed with Dextrose)</td>
</tr>
<tr>
<td>Visibility during embolization</td>
<td>Micronized tantalum provides radio-opacity</td>
<td>Lipidol provides radio-opacity and desired polymerization time</td>
</tr>
<tr>
<td>Mechanism</td>
<td>Precipitation, nondhesive.³⁰</td>
<td>Fast polymerization (on exposure to the ionic environment of the blood, Adhesive)³¹</td>
</tr>
<tr>
<td>Catheter make</td>
<td>Requires DMSO compatible catheters³¹</td>
<td>No catheter compatibility issues</td>
</tr>
<tr>
<td>Preparation time</td>
<td>Longer (shaken for at least 20 minutes in a mixer to obtain a homogenous solution with tantalum powder)</td>
<td>Short</td>
</tr>
<tr>
<td>Nontarget embolization risk</td>
<td>Lesser (allows controlled administration)</td>
<td>Relatively more</td>
</tr>
<tr>
<td>“Catheter stuck” risk</td>
<td>Lesser</td>
<td>More</td>
</tr>
<tr>
<td>Cost</td>
<td>More</td>
<td>Lesser</td>
</tr>
<tr>
<td>Postembolization infection risk</td>
<td>Minimal</td>
<td>More (due to subcutaneous or intramuscular accumulation)³²</td>
</tr>
</tbody>
</table>

Abbreviations: AVF, arteriovenous fistula; AVM, arteriovenous malformation; EVOH, ethylene vinyl alcohol copolymer; n-BCA, n-butyl cyanoacrylate.
complete obliteration subsequently, not only by permitting longer dwell time of the administered embolic agents (through direct cutaneous or transvenous approaches), but also by minimizing risk of inadvertent embolization to the normal venous circulation.°Lv et al achieved 93.3% obliteration rates of AVMs using TRAE technique, when supplemented with transarterial embo- lization initially, underscoring the importance of this dual approach.°°However, caution must be exercised with these approaches, as there is real risk of inability to access the nidus subsequently through the previously coiled feeding artery (if the need arises, as in failed transvenous or percutaneous approach) with risk of additional recruitment of arteries and worsening of AVM.°°

The favorable and unfavorable angioarchitecture for transarterial approach is summarized in °Table 5.

Transvenous coil embolization is a preferred technique in cases with a demonstrable dominant outflow vein (DOV), as in Cho do Type 2 AVM (°Fig. 3). The transvenous coil

Table 4 Cho–Do classification system with influence on mode of endovascular management.

<table>
<thead>
<tr>
<th>AVM nomenclature</th>
<th>Nidus type</th>
<th>Morphological description</th>
<th>Preferred endovascular management approach</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arteriovenous</td>
<td>I</td>
<td>≤ 3 feeding arteries, single outflow vein</td>
<td>Transarterial or transvenous</td>
</tr>
<tr>
<td>Arteriovenous</td>
<td>II</td>
<td>&gt; 3 feeding arteries, single dominant outflow vein</td>
<td>Transvenous</td>
</tr>
<tr>
<td>Arteriovenous</td>
<td>IIIa</td>
<td>Multiple feeding arteries, multiple outflow veins</td>
<td>Transarterial</td>
</tr>
<tr>
<td>Dilated arteriovenous</td>
<td>IIIb (IIIa + dilated vessels)</td>
<td>Dilated multiple feeding arteries, dilated multiple outflow veins</td>
<td>Transarterial, transvenous or percutaneous</td>
</tr>
</tbody>
</table>

Abbreviation: AVM, arteriovenous malformation.
placement allows stabilization of the thrombus in the DOV, with concurrent administration of liquid embolic agent into the nidus and adjacent part of vein through either a direct percutaneous approach or catheter parked close to the nidus through a transvenous approach. The low pressure “sump” which is considered to be a very strong stimulus to development of collateral arterial channels is effectively eliminated using transvenous approach and hence provides best opportunity for long-term cure.

The destruction of the nidus endothelium with consequent inability of release of angiogenic factors prevents vessel recruitment and recurrence of AVM following ethanol sclerotherapy.18 The intense sclerosing effect of the ethanol can be utilized to much benefit in the treatment of an AVM, provided the agent remains localized to the nidus. This can be achieved with flow reduction techniques using coils, plugs, or balloons.17 Jackson et al,28 Cho et al,26 and Linden et al39 demonstrated successful treatment of PAVMs through a transvenous approach using ethanol in conjunction with coil embolization. Yakes classified PAVMs into six types (Ia, IIa, IIb, IIIa, IIIb and IV) based on nidus angioarchitecture, which is limited to ethanol use as the sole embolizing agent.
or in conjunction with mechanical occlusion (coils, or plugs), depending on the nidus type. Risks associated with embolization, including surrounding tissue ischemia, nontarget embolization, intra or postprocedural vascular rupture and incomplete embolization of the AVM, warrant assessment of individualized benefit risk ratio and case-based treatment strategy. The sudden hemodynamic changes encountered following complete AVM embolization in one sitting is the likely explanation of post embolization rupture and bleed. Inadvertent nontargeted downstream embolization of peripheral, pulmonary, coronary, and cerebral circulation can lead to limb ischemia, pulmonary embolism (PE), acute coronary syndrome (ACS) and stroke, respectively. Recanalization consequent to recruitment of additional vessels following incompletely embolized AVM is not uncommon. Also, there is risk of coil embolization failure consequent to coagulopathies or anticoagulation therapy. Intense pain, need of general anesthesia, potential for intense skin necrosis, PE, and arterial hypertension are some of the important drawbacks with ethanol sclerosing agent. The obliteration of the nidus is important to achieving complete cure and minimizing recurrence risk in patients with PAVM. Failure to navigate catheter to the nidus (consequent to unfavorable angioarchitecture) merits consideration of surgery to achieve higher cure rates. Outcomes following standalone endovascular treatment vary considerably with small PAVM (with a single draining vein) demonstrating high cure rates, whereas large, diffuse AVMs documenting suboptimal results, necessitating multimodality management (including surgical intervention). The best clinical outcome can be achieved if management is undertaken by a multidisciplinary team comprising interventional radiologists, plastic/vascular surgeon and dermatologist. Lower recurrence rates are documented if aggressive embolization is combined with surgical resection in appropriately selected cases. Although the classical Schobinger stage I lesion is clinically quiescent and is usually managed with observation and close follow-up, the extensive diffuse stage I lesions show better outcome with application of compressive stockings.

**Conclusion**

The peripheral HFVMs show varied clinical presentation and frequently pose a diagnostic and therapeutic challenge. While the ISSVA classification system is the most commonly accepted system for classifying congenital vascular anomalies in clinical practice, the Cho–Do et al classification is of utmost help in guiding optimal treatment in PAVMs. Although transarterial approach remains the most commonly employed route for PAVM embolization, the role of
transvenous and direct percutaneous approach is increasing.
The endovascular approach undertaken depends on angioarchi-
tecture of the AVM.

Conflict of Interest
None declared.

Acknowledgment
Figs. 1, 3 and 7 have been drawn in original by Dr. Harshitha Kramadhari (one of the authors of this article).

References
3 Mulliken JB, Glowacki J. Hemangiomas and vascular malforma-
6 Wassef M, Blei F, Adams D, et al. ISSVA Board and Scientific Committee. Vascular anomalies classification: recommenda-
8 Yakes WF. Yakes’ AVM classification system. J Vasc Interv Radiol 2015;26:S224
9 Dubois J, Garell I. Imaging and therapeutic approach of hemangio-
14 Kohout MP, Hansen M, Pribaz JJ, Mulliken JB. Arteriovenous malformations of the head and neck: natural history and man-
18 Yakes WF. Endovascular management of high-flow arterio-
23 Dunham GM, Ingraham CR, Maki JH, Vaidya SS. Finding the nidus: detection and workup of non-central nervous system arterio-
venous malformations. Radiographics 2016;36(3):891–903
28 Cho SK, Do YS, Kim DI, et al. Peripheral arteriovenous malfor-
29 Strauss I, Haim O, Umanzky D, et al. Impact on onyx embol-
ization on radiosurgical management of cerebral arterio-
33 Pimpalwar S. Vascular malformations: approach by an inter-
vventional radiologist. Semin Plast Surg 2014;28(2):91–103
34 Lv X, Song C, He H, Jiang C, Li Y. Transvenous retrograde AVM embolization: Indications, techniques, complications and out-
comes. Interv Neuroradiol 2017;23(5):504–509
37 Lee BB. New approaches to the treatment of congenital vas-
cular malformations (CMVs)—a single centre experience. Eur J Vasc Endovasc Surg 2005;30(2):184–197

Endovascular Management Strategies, Peripheral Arteriovenous Malformations


